Systemic lupus erythematosus (SLE) is a chronic inflammatory disease that may affect the joints, skin, kidneys, lungs, nervous system, and serous membranes and/or other organs. Lymphadenopathy is characterized by changes in the characteristics and size of the lymph nodes. It results from reticuloendothelial proliferation secondary to inflammation, infection, or malignancies. Lymphadenopathy is common in SLE. It has been reported that lymph node enlargement is observed in 25-67% of SLE patients. We reported this thirty-three-year patient with presented with lymph node enlargement in cervical, axillary, and inguinal, joint pain, renal involvement and respiratory involvement diagnosed as Systemic lupus erythematosus according to ACR/EULAR criteria immunological and clinical domain SLICC (systemic lupus international collaborating clinics. In conclusion, lymphadenopathy is a manifestation in SLE. As illustrated by the case presented here, it can precede the diagnosis of SLE by many years; It is possible that the factors that induce lymph node proliferation are also responsible for the development of autoantibodies.

Background/Aims In November 2019, there were abundant cases of COVID-19 for which the first case was reported in Wuhan, China. Cytokine storm syndrome is the severe immune reaction that may cause a severe tissue response in COVID-19 patients. Colchicine has an important role in inhibiting activation of NLRP3 inflammasome that predispose to decrease cytokine production. This study aimed to evaluate whether colchicine is effective in treatment of COVID-19 patients or not. Methods A randomized, open labelled, clinical trial of colchicine for the treatment of COVID-19, allocated between 8th May to 18th June 2021. Patients with mild, moderate, or severe COVID-19 infection; confirmed by real time PCR (RT-PCR) and/or lung involvement confirmed by computed tomography scan compatible with COVID-19. The colchicine tablet dosage was 0.5mg twice daily for 14 days added to the standard treatment versus control group who received standard treatment without colchicine, with the trial registration ID: NCT04867226. The study was conducted in Erbil City, Iraq with the endpoints being clinical, laboratory parameters duration of hospitalization and side effects. Results 80 patients participated in the study. Fewer patients in the colchicine group had musculoskeletal symptoms (17.5%, p: 0.001) in comparison to the patients, who received control treatment. The serum ferritin level in most of patients who treated with colchicine returned to normal in contrast to the control group, whose serum ferritin level was still high (p: 0.041). Similarly, the average of CRP and D-dimer after treatment among the colchicine group participants was significantly lower than the control group, the P-values were 0.011 and 0.043, respectively. The colchicine group patients stayed for a shorter duration at the hospital (18.4 days) compared to the control group (24.24 days). P-value was 0.009. In addition to that the response and cure rate were higher in the colchicine group (56%) in the comparison to control group (43.1%) Table 1: Laboratory Parameters with musculoskeletal symptoms and duration of hospitalization of both Treatment Regimens.. Conclusion The colchicine drug can be effective in treating patients with COVID-19 infection by improving musculoskeletal symptoms and inhibiting inflammatory biomarkers; it is also effective in reducing duration of hospitalization. Disclosure A.M. jalal: None. S. Aref: None. D. Albustany: None.